Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Partially Remote
Drugs
Locations
Clinical Specialty
901-920 of 998 trials

Schizophrenia and Alcohol Use Disorder: Tirzepatide Study

We are investigating whether tirzepatide can help reduce alcohol consumption in individuals with schizophrenia and alcohol use disorder. This study compares tirzepatide to a placebo to assess its effects.

Schizophrenia and Alcohol Use Disorder6-12 monthsEfficacy phase (II)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteEndocrinologyPsychiatry

Cholangiocarcinoma: Chemo and Immunotherapy Study

We are exploring a combination of chemotherapy and immunotherapy for patients with locally advanced cholangiocarcinoma before surgery. The study aims to see if this approach can lower the risk of cancer returning after treatment.

Cholangiocarcinoma1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteOncology

Heart Failure: Empagliflozin and Dapagliflozin Study

We are investigating how two medications may improve outcomes for patients hospitalized with acute heart failure. The study looks at their effects on heart function and other health indicators.

Acute Decompensated Heart Failure>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesPartially RemoteCardiologyInternal Medicine

Erosive Esophagitis: Linaprazan Glurate vs. Lansoprazole

We are studying whether linaprazan glurate can heal erosive esophagitis in patients with GERD better than lansoprazole. This trial aims to evaluate the effectiveness and safety of the new treatment.

Erosive Esophagitis≤3 monthsConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterology

Breast Cancer: Inavolisib Treatment Study

We are testing a new treatment using Inavolisib for patients with early-stage, PIK3CA-mutated breast cancer. The study aims to evaluate how safe and effective this treatment is for participants.

Early-Stage Breast Cancer6-12 monthsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncology

HIV Treatment: Venetoclax Study

We are testing the safety of a medication called venetoclax in people living with HIV who are on antiretroviral therapy. The aim is to see if it can help reduce the size of the HIV reservoir in the body.

HIV-1 Disease1-2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyInfectious Diseases

Knee Osteoarthritis: Study of 4P004 Treatment

We are investigating whether the treatment 4P004 can reduce pain and improve function in people with knee synovitis and osteoarthritis. Participants will receive either the treatment or a placebo to assess its effectiveness and safety.

Knee Synovitis and Osteoarthritis≤3 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemoteOrthopedics and TraumatologyRheumatology

Narcolepsy and Idiopathic Hypersomnia: ORX750 Study

We are testing a new medication, ORX750, to see if it is safe and well-tolerated in people with narcolepsy and idiopathic hypersomnia. This study will help us understand how the drug works in the body.

Narcolepsy with CataplexyIdiopathic Hypersomnia3-6 monthsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Cardiac Arrest: Landiolol Treatment Study

We are testing whether adding landiolol can help patients who have had a cardiac arrest regain a stable heartbeat faster. This study will also look at overall survival and safety outcomes.

Cardiac Arrest and Ventricular Fibrillation6-12 monthsEfficacy phase (II)6-10 visitsStandard MedicinesPartially RemoteCardiologyInternal Medicine

Chronic Graft-Versus-Host Disease: Axatilimab Treatment Study

We are comparing a new treatment called axatilimab to the best available therapy for patients with chronic graft-versus-host disease who have not responded to previous treatments. The goal is to see if axatilimab is more effective and safer.

Chronic Graft-Versus-Host Disease>2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

X-ALD: Pramipexole for Leg Symptoms

We are investigating whether pramipexole can help reduce restless leg symptoms in women with X-linked Adrenoleukodystrophy. This study aims to improve their sleep and walking performance.

X-linked AdrenoleukodystrophyRestless Legs Syndrome3-6 monthsMonitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurology

Advanced Clear-Cell Renal Carcinoma: Digital Monitoring with Cabozantinib and Nivolumab

We are studying how digital tracking of symptoms can help adjust treatments for patients with advanced clear-cell renal carcinoma receiving Cabozantinib and Nivolumab. This may improve their overall health and quality of life during treatment.

Kidney Cancer>2 yearsMonitoring phase (IV)16-20 visitsNo PlaceboStandard MedicinesPartially RemoteInternal MedicineOncologyUrology

Hypertension and Obesity: Orforglipron Study

We are investigating a new medication, Orforglipron, for people with hypertension who are also overweight or obese. The goal is to see if it can safely help manage their blood pressure.

High Blood Pressure1-2 yearsConfirmation phase (III)Investigational MedicinesPartially RemoteEndocrinologyInternal Medicine

Pleural Mesothelioma: Ivonescimab Treatment Study

We are evaluating ivonescimab for patients with relapsing pleural mesothelioma who have already been treated with immunotherapy and chemotherapy. The study aims to assess its safety and effectiveness as a potential new treatment option.

Pleural Mesothelioma>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Chronic Heart Failure: Ferric Derisomaltose Treatment

We are studying whether ferric derisomaltose can improve heart health and reduce hospitalizations in people with iron deficiency and chronic heart failure. This trial compares it to no intravenous iron treatment.

Chronic Heart Failure1-2 yearsConfirmation phase (III)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Chronic Hepatitis Delta: Brelovitug Treatment Study

We are studying a new medication, brelovitug, for people with chronic hepatitis delta infection. The trial aims to see if it works better than waiting for treatment and to evaluate its safety.

Hepatitis D>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHepatology

Tozorakimab for Uncontrolled Asthma

We are studying whether different doses of tozorakimab can help adults with uncontrolled asthma reduce severe attacks. This trial compares the medication to a placebo to evaluate its effectiveness and safety.

Asthma1-2 yearsEfficacy phase (II)Investigational MedicinesPartially RemoteAllergologyPulmonology

Neoadjuvant Chemo-Immunotherapy for Stage III PD-L1 Positive NSCLC

We are studying a combination of tislelizumab and chemotherapy for patients with stage III PD-L1 positive lung cancer. The aim is to see if this treatment improves surgery success and survival rates.

Stage III Non-Small Cell Lung CancerEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteOncologyPulmonology

Chronic Heart Failure: Omecamtiv Mecarbil Study

We are testing a new medication for people with chronic heart failure and severely reduced heart function. The study aims to see if it can improve heart health outcomes compared to a placebo.

Heart Failure with Reduced Ejection Fraction>2 yearsConfirmation phase (III)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Cervical Dystonia: IPN10200 Treatment Study

We are studying the effects of IPN10200 on reducing symptoms of cervical dystonia in adults. This trial will help us understand if it can improve pain and disability compared to a placebo.

Cervical Dystonia6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemoteNeurologyOrthopedics and Traumatology